Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01546558
First received: February 27, 2012
Last updated: July 9, 2012
Last verified: July 2012

February 27, 2012
July 9, 2012
February 2012
March 2012   (final data collection date for primary outcome measure)
  • Maximum observed plasma concentration (Cmax) of metformin [ Time Frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5 and 10 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin [ Time Frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5 and 10 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01546558 on ClinicalTrials.gov Archive Site
  • Number of participants with adverse events [ Time Frame: From time of signed informed consent to time of follow-up phone call, an expected average of 5 weeks ] [ Designated as safety issue: Yes ]
  • Maximum observed plasma concentration (Cmax) of ranolazine and metabolites [ Time Frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 10 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites [ Time Frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 10 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
A Phase 1, Open-label, Single Cohort, Two-Period Fixed Sequence Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg Twice Daily in Subjects With Type 2 Diabetes Mellitus

The purpose of this study is to evaluate the effect of steady-state ranolazine 500 mg bid on the steady state pharmacokinetics (PK) of metformin in subjects with type 2 diabetes mellitus (T2DM).

The primary objective of this study is as follows:

• To evaluate the effect of steady-state ranolazine 500 mg twice daily (bid) on the steady state pharmacokinetics (PK) of metformin in subjects with T2DM.

The secondary objectives of this study are as follows:

  • To examine the safety and tolerability of metformin when co administered with ranolazine 500 mg bid at steady-state in subjects with T2DM.
  • To determine the steady-state PK of ranolazine 500 mg bid in subjects with T2DM receiving metformin.
Interventional
Phase 1
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Type 2 Diabetes Mellitus
  • Drug: Metformin
    Metformin 1000 mg bid on Days 1-10
    Other Name: Glucophage
  • Drug: Ranolazine
    Ranolazine 500 mg bid on Days 6-10
    Other Name: Ranexa
Experimental: Metformin, Ranolazine

Single cohort, 2-period study:

  • Period 1, metformin 1000 mg bid on Days 1-5
  • Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10
Interventions:
  • Drug: Metformin
  • Drug: Ranolazine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females, 30 to 65 years old, inclusive
  • Documented history of T2DM
  • HbA1c 6.5%-10%, inclusive
  • Fasting serum glucose ≤ 270 mg/dL at Screening
  • Fasting C-peptide ≥ 1 ng/mL at Screening
  • Stable metformin monotherapy (metformin ≥ 1500 mg total daily dose for at least 4 weeks prior to Screening)
  • Body mass index (BMI) 25 to 40 kg/m2, inclusive, at Screening
  • Creatinine Clearance > 80 mL/min at Screening
  • Females of child-bearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1 and must agree to use highly effective contraception methods from Screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug

Exclusion Criteria:

  • Type 1 Diabetes Mellitus (T1DM)
  • Use of insulin therapy < 3 months prior to Screening
  • History of ketoacidosis, ketosis-prone diabetes, or lactic acidosis
  • Clinically significant complications of diabetes
  • History of hypoglycemia
  • Any non-insulin antidiabetic therapy (other than metformin) < 2 months prior to Screening
  • Any clinically significant cardiovascular event < 2 months prior to Screening
  • Clinically significant, inadequately controlled, or unstable hypertension
  • Hospitalization < 2 months prior to Screening or major surgery < 3 months prior to Screening
  • History of gastrointestinal disease or surgery that could impact drug absorption
  • History of substance of alcohol or substance abuse
  • Positive urine drug screen for drugs of abuse
  • Positive alcohol breath test
  • Any other clinically significant existing medical or psychiatric condition or one requiring further evaluation
  • Treatment with selected medications
  • Hemoglobin < 12 g/dL for males; or < 11 g/dL for females at Screening
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5x upper limits of normal
  • Clinically significant history of hepatic disease or evidence of hepatic impairment
  • Positive blood screen for hepatitis C or hepatitis B
  • QTc interval > 500 msec at Screening
  • Females who are pregnant or are breastfeeding
Both
30 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01546558
GS-US-259-0143
No
Gilead Sciences
Gilead Sciences
Not Provided
Principal Investigator: Axel Juan, MD SeaView Research, Inc.
Gilead Sciences
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP